Barinthus Biotherapeutics plc (BRNS) — Cash Flow Quality Index

Latest as of September 2022: 1.45x

Barinthus Biotherapeutics plc (BRNS) has a Cash Flow Quality Index of 1.45x as of September 2022. Operating cash flow of $11.88 Million exceeds net income of $8.22 Million, indicating high earnings quality where cash backs reported profits. Also explore Barinthus Biotherapeutics plc total assets for the complete picture of this company's asset base.

Cash Flow Quality Index

1.45x
Operating CF / Net Income

Operating Cash Flow

$11.88 Million
USD

Net Income

$8.22 Million
USD

Data as of

Sep 2022
Most recent filing

Barinthus Biotherapeutics plc Cash Flow Quality Index (2022–2022)

Historical Cash Flow Quality Index for Barinthus Biotherapeutics plc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Barinthus Biotherapeutics plc tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Barinthus Biotherapeutics plc (2022–2022)

Year-by-year earnings quality comparison for Barinthus Biotherapeutics plc. For live market cap and the full company financial profile, see BRNS market cap overview.

Year Quality Index Operating CF (USD) Net Income YoY Change
2022 -2.71x $-14.43 Million $5.32 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.